The Unexpected Roles of Aurora A Kinase in Gliobastoma Recurrences

Overview

Journal Target Oncol

Specialty Oncology

Date 2016 Aug 31

PMID 27573024

Citations 8

Authors

Estelle Willems

Arnaud Lombard

Matthias Dedobbeleer

Nicolas Goffart

Bernard Rogister

Affiliations

Soon will be listed here.

Abstract

The main obstacle for the cure of glioblastoma (GBM) is systematic tumor recurrence after treatment. More than 90 % of GBM tumors are indeed recurrent within 5 years after diagnosis and treatment. We urgently need new therapies to specifically address these deadly relapses. A major advance in the understanding of GBM recurrence is the identification of GBM-Initiating Cells (GIC), characterized by their abilities for self-renewal, multilineage differentiation, and proliferation. It appears that these features of GIC could be modulated by the mitotic kinase Aurora A (AurA). Indeed, besides its role in mitosis, AurA has recently been identified to regulate alternative functions like cell polarity, asymmetric cell division, and epithelial to mesenchymal transition. All these properties may help explain GBM therapeutic resistance and recurrence. In this review, we make the hypothesis that AurA could significantly contribute to GBM recurrences and we focus on the possible roles of AurA in GIC.

Citing Articles

Mitotic Kinases Aurora-A, Plk1, and Cdk1 Interact with Elk-1 Transcription Factor through the N-Terminal Domain.

Uyar O, Babal Y, Yilmaz B, Kurnaz I Int J Cell Biol. 2024; 2024:6798897.

PMID: 38716144 PMC: 11074830. DOI: 10.1155/2024/6798897.

Interrater Agreement of BT-RADS for Evaluation of Follow-up MRI in Patients with Treated Primary Brain Tumor.

Essien M, Cooper M, Gore A, Min T, Risk B, Sadigh G AJNR Am J Neuroradiol. 2024; 45(9):1308-1315.

PMID: 38684320 PMC: 11392352. DOI: 10.3174/ajnr.A8322.

vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target.

Manzanares-Guzman A, Lugo-Fabres P, Camacho-Villegas T Antibodies (Basel). 2024; 13(1).

PMID: 38534215 PMC: 10967338. DOI: 10.3390/antib13010025.

Autocrine regulation of tumor cell repopulation by Hsp70-HMGB1 alarmin complex.

Sverchinsky D, Alhasan B, Mikeladze M, Lazarev V, Kuznetcova L, Morshneva A J Exp Clin Cancer Res. 2023; 42(1):279.

PMID: 37880798 PMC: 10598926. DOI: 10.1186/s13046-023-02857-0.

Dual roles of oxostephanine as an Aurora kinase inhibitor and angiogenesis suppressor.

Tran T, Vu L, Nguyen H, Pham H, Do X, Than U Int J Mol Med. 2022; 50(5).

PMID: 36102296 PMC: 9558763. DOI: 10.3892/ijmm.2022.5189.

References

Fletcher G, Brokx R, Denny T, Hembrough T, Plum S, Fogler W . ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther. 2010; 10(1):126-37. DOI: 10.1158/1535-7163.MCT-10-0574. View

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

Johnston C, Hirono K, Prehoda K, Doe C . Identification of an Aurora-A/PinsLINKER/Dlg spindle orientation pathway using induced cell polarity in S2 cells. Cell. 2009; 138(6):1150-63. PMC: 2789599. DOI: 10.1016/j.cell.2009.07.041. View

Li N, Maly D, Chanthery Y, Sirkis D, Nakamura J, Berger M . Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma. Mol Cancer Ther. 2014; 14(2):419-28. PMC: 4326592. DOI: 10.1158/1535-7163.MCT-14-0526. View

Barone A, Sengupta R, Warrington N, Smith E, Wen P, Brekken R . Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. Oncotarget. 2014; 5(20):9811-22. PMC: 4259439. DOI: 10.18632/oncotarget.2443. View

Hochegger H, Hegarat N, Pereira-Leal J . Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle. Open Biol. 2013; 3(3):120185. PMC: 3718339. DOI: 10.1098/rsob.120185. View

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

Chen J, Li Y, Yu T, McKay R, Burns D, Kernie S . A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012; 488(7412):522-6. PMC: 3427400. DOI: 10.1038/nature11287. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

10.

Samaras V, Stamatelli A, Samaras E, Arnaoutoglou C, Arnaoutoglou M, Stergiou I . Comparative immunohistochemical analysis of aurora-A and aurora-B expression in human glioblastomas. Associations with proliferative activity and clinicopathological features. Pathol Res Pract. 2009; 205(11):765-73. DOI: 10.1016/j.prp.2009.06.011. View

11.

Van Brocklyn J, Wojton J, Meisen W, Kellough D, Ecsedy J, Kaur B . Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. Cancer Res. 2014; 74(19):5364-70. PMC: 4528677. DOI: 10.1158/0008-5472.CAN-14-0386. View

12.

Nikonova A, Astsaturov I, Serebriiskii I, Dunbrack Jr R, Golemis E . Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci. 2012; 70(4):661-87. PMC: 3607959. DOI: 10.1007/s00018-012-1073-7. View

13.

Gustafson W, Meyerowitz J, Nekritz E, Chen J, Benes C, Charron E . Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 2014; 26(3):414-427. PMC: 4160413. DOI: 10.1016/j.ccr.2014.07.015. View

14.

Chaichana K, Zamora-Berridi G, Camara-Quintana J, Quinones-Hinojosa A . Neurosphere assays: growth factors and hormone differences in tumor and nontumor studies. Stem Cells. 2006; 24(12):2851-7. DOI: 10.1634/stemcells.2006-0399. View

15.

Wang X, Zhou Y, Qiao W, Tominaga Y, Ouchi M, Ouchi T . Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene. 2006; 25(54):7148-58. DOI: 10.1038/sj.onc.1209707. View

16.

Heddleston J, Li Z, McLendon R, Hjelmeland A, Rich J . The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009; 8(20):3274-84. PMC: 2825672. DOI: 10.4161/cc.8.20.9701. View

17.

Elias M, Tozer K, Silber J, Mikheeva S, Deng M, Morrison R . TWIST is expressed in human gliomas and promotes invasion. Neoplasia. 2005; 7(9):824-37. PMC: 1501937. DOI: 10.1593/neo.04352. View

18.

Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer M . Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res. 2010; 70(11):4655-65. DOI: 10.1158/0008-5472.CAN-09-3953. View

19.

Wu M, Kwon H, Rattis F, Blum J, Zhao C, Ashkenazi R . Imaging hematopoietic precursor division in real time. Cell Stem Cell. 2008; 1(5):541-54. PMC: 2267762. DOI: 10.1016/j.stem.2007.08.009. View

20.

de Almeida Sassi F, Brunetto A, Schwartsmann G, Roesler R, Abujamra A . Glioma revisited: from neurogenesis and cancer stem cells to the epigenetic regulation of the niche. J Oncol. 2012; 2012:537861. PMC: 3438806. DOI: 10.1155/2012/537861. View